Table 1.
Baseline Characteristics. a
| Patients reporting barriers to care, No. (%) | |||
|---|---|---|---|
| Yes (n = 62) | No (n = 140) | P value | |
| Age, y, mean (SD) | 57.0 (9.2) | 60.8 (10.2) | .012 |
| Sex | .018 | ||
| Male | 45 (72.6) | 121 (86.4) | |
| Female | 17 (27.4) | 19 (13.6) | |
| Race | .067 | ||
| White | 50 (80.7) | 126 (90.0) | |
| Non-White | 12 (19.3) | 14 (10.0) | |
| Marital status | .015 | ||
| Married | 35 (57.4) | 103 (74.6) | |
| Not married | 26 (42.6) | 35 (25.4) | |
| Education | .091 | ||
| High school or less | 44 (73.3) | 80 (58.0) | |
| College graduate | 11 (18.3) | 33 (23.9) | |
| Postgraduate/ professional degree | 5 (8.3) | 25 (18.1) | |
| Insurance | .022 | ||
| Private | 31 (50.0) | 84 (60.0) | |
| Uninsured | 5 (8.1) | 3 (2.1) | |
| Medicare | 17 (27.4) | 46 (32.9) | |
| Medicaid | 9 (14.5) | 7 (5.0) | |
| Currently work for pay | 27 (44.3) | 68 (49.3) | .514 |
| Distance to hospital, miles, mean (SD) | 72.8 (71.6) | 69.0 (57.6) | .706 |
| History | |||
| Tobacco use | 40 (64.5) | 81 (61.4) | .673 |
| Alcohol use | 32 (51.6) | 67 (47.9) | .622 |
| Comorbid | |||
| Depression | 16 (25.8) | 13 (9.6) | .003 |
| Anxiety | 17 (27.4) | 17 (12.5) | .010 |
| Tumor site | .890 | ||
| Oral cavity | 21 (33.9) | 53 (37.9) | |
| Oropharynx b | 29 (46.8) | 67 (47.9) | |
| Hypopharynx | 2 (3.2) | 4 (2.9) | |
| Larynx | 7 (11.3) | 10 (7.1) | |
| Other | 3 (4.8) | 6 (4.3) | |
| Overall stage: AJCC (7th ed) | .859 | ||
| Early: I/II | 18 (30.5) | 38 (29.2) | |
| Advanced: III/IV | 41 (69.5) | 92 (70.8) | |
| Treatment | .621 | ||
| Surgery alone | 21 (33.9) | 37 (26.6) | |
| Surgery + adjuvant RT | 7 (11.3) | 18 (13.0) | |
| Surgery + adjuvant CRT | 11 (17.7) | 37 (26.6) | |
| RT or chemotherapy alone | 6 (9.7) | 10 (7.2) | |
| CRT | 17 (27.4) | 37 (26.6) | |
| No. of treatment modalities | .235 | ||
| 1 | 27 (43.6) | 45 (32.9) | |
| 2 | 24 (38.7) | 55 (40.1) | |
| 3 | 11 (17.7) | 37 (27.0) | |
Abbreviations: CRT, chemoradiation therapy; RT, radiation therapy.
a
Bold indicates P < .05.
b
p16 status was available for 35 patients with oropharyngeal squamous cell carcinoma.